Trastuzumab (herceptin) and HER2-positive breast cancer

被引:8
|
作者
Murray, S
机构
关键词
D O I
10.1503/cmaj.051452
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:36 / 37
页数:2
相关论文
共 50 条
  • [41] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [42] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [43] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [44] Neratinib after trastuzumab in patients with HER2-positive breast cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    LANCET ONCOLOGY, 2016, 17 (05): : E176 - E176
  • [45] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [46] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [47] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Krop, Ian
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 610 - 621
  • [48] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03): : 297 - 299
  • [49] Continued trastuzumab therapy for patients with HER2-positive breast cancer
    Haslbauer, F.
    EJC SUPPLEMENTS, 2008, 6 (07): : 221 - 221
  • [50] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104